On
The China Patent Award has been successfully selected for 24 times since 1989. It mainly focuses on key industries and core technologies in key fields, highlights the 'big country's important tools' in the manufacturing industry, and solves 'stuck neck' technical problems. It represents the highest technological level in the industry and is our country's knowledge An important manifestation of the achievements of a country with strong property rights.
A total of 29 invention and utility model patents were awarded the China Patent Gold Award at this conference. The invention patent 'EGFR inhibitors and their preparation and application' (patent number: ZL 201580045311.2) stood out from more than 2,400 participating patents and won the China Patent Gold Award, demonstrating the social value of Ametinib and the innovative strength of
Ametinib: Small molecule meets big needs
Lung cancer is currently the cancer with the highest incidence rate in my country, and there is an urgent clinical need for third-generation EGFR-targeted drugs. Through innovative research and development,
As the first third-generation EGFR inhibitor in
Intellectual Property: High-value patents protect full-cycle operations
The company deeply implements high-value patent cultivation and management standards, and conducts a full research and development cycle and global intellectual property layout for each innovative drug. Combining the results of innovative products at different stages of research and development, the patent management department conducts a series of patent layouts for different technical themes such as pharmaceutical compounds, pharmaceutical salt forms/crystalline forms, pharmaceutical preparations or preparation processes, and new pharmaceutical uses, and conducts a series of patent layouts on core Patents apply for diversified protection in many overseas countries. Currently, the award-winning patent for Ametinib has entered 13 countries and regions around the world, and has been authorized in
Up to now,
Contact:
Tel: 0518-83096666
(C) 2023 Electronic News Publishing, source